Disc Medicine, Inc. (IRON)

30.36 -0.41 (-1.33%) At close: 04:00PM EDT

Disc Medicine, Inc.

321 Arsenal Street
Suite 101
Watertown, MA 02472
United States
617 674 9274
https://www.discmedicine.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 78

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Donald William Nicholson Ph.D.	Executive Chairman	164k	N/A	1958
Dr. John D. Quisel Esq., J.D., Ph.D.	CEO, President & Director	903.46k	N/A	1971
Dr. William Jacob Savage M.D., Ph.D.	Chief Medical Officer	687.74k	N/A	1974
Dr. Brian MacDonald ChB, MB, Ph.D.	Founder & Chair of Scientific Advisory Board	88.54k	N/A	1960
Ms. Jean M. Franchi	Chief Financial Officer	N/A	N/A	1966
Mr. Jonathan Yu M.B.A.	Chief Opearating Officer	539.32k	N/A	1981
Dr. Rahul Khara J.D., Pharm.D.	General Counsel, Compliance Officer & Secretary	N/A	N/A	1982
Mr. Srikanth Venkatraman Ph.D.	Senior VP & Head of Chemistry	N/A	N/A	N/A
Ms. Hua Yang Ph.D.	Senior Vice President of Nonclinical Development	N/A	N/A	N/A
Ms. Pamela Stephenson M.P.H.	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Corporate governance

Disc Medicine, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.